Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: March 30, 2026, 3:50 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 530207 | NSE: BRAWN

Brawn Biotech Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹62.18Undervalued by 198.94%vs CMP ₹20.80

P/E (15.0) × ROE (41.3%) × BV (₹12.30) × DY (2.00%)

Defaults: P/E=15

₹51.96Undervalued by 149.81%vs CMP ₹20.80
MoS: +60% (Strong)Confidence: 23/100 (Low)Models: 1 Under, 1 Fair, 1 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹89.0949%Under (+328.3%)
Net Asset ValueAssets₹12.2929%Over (-40.9%)
Revenue MultipleRevenue₹22.3622%Fair (+7.5%)
Consensus (3 models)₹51.96100%Undervalued
Key Drivers: EPS CAGR 43.3% lifts DCF — verify sustainability. | Wide model spread (₹12–₹89) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 43.3% · Defaults: P/E=15

*Investments are subject to market risks

Investment Snapshot

62
Brawn Biotech Ltd scores 62/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health72/100 · Strong
ROCE 42.5% ExcellentROE 41.3% ExcellentD/E 0.00 Low debtInterest Coverage 0.0x RiskyProfitable 0/5 years Inconsistent
Smart Money50/100 · Moderate
Promoter holding at 53.4% Stable
Earnings Quality40/100 · Moderate
OPM stable around -11% SteadyWorking capital: 216 days Capital intensive
Quarterly Momentum70/100 · Strong
Revenue (4Q): +18% YoY GrowingOPM: -0.2% (up 10.2% YoY) Margin expansion
Industry Rank75/100 · Strong
ROCE 42.5% vs industry 16.4% Above peersROE 41.3% vs industry 15.2% Above peers3Y sales CAGR: 16% Moderate

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: March 30, 2026, 3:50 am

Market Cap 6.26 Cr.
Current Price 20.8
Intrinsic Value₹51.96
High / Low 24.4/15.7
Stock P/E
Book Value 12.3
Dividend Yield0.00 %
ROCE42.5 %
ROE41.3 %
Face Value 10.0
PEG Ratio0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Brawn Biotech Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Lactose (India) Ltd 106 Cr. 84.2 137/76.021.9 49.60.00 %12.9 %9.69 % 10.0
MPS Pharmaa Ltd 3.15 Cr. 1.65 3.17/1.57 0.330.00 %9.79 %59.0 % 10.0
Gujarat Themis Biosyn Ltd 2,692 Cr. 247 479/22256.3 24.30.27 %27.3 %21.7 % 1.00
Gujarat Terce Laboratories Ltd 25.3 Cr. 32.5 68.4/29.0 10.10.00 %41.4 %14.6 % 10.0
Gujarat Inject (Kerala) Ltd 120 Cr. 82.1 82.1/17.0481 6.930.00 %13.5 %11.0 % 10.0
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Brawn Biotech Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 6.314.757.292.922.843.454.063.303.842.265.804.894.31
Expenses 6.324.887.453.313.423.844.563.624.242.815.624.884.32
Operating Profit -0.01-0.13-0.16-0.39-0.58-0.39-0.50-0.32-0.40-0.550.180.01-0.01
OPM % -0.16%-2.74%-2.19%-13.36%-20.42%-11.30%-12.32%-9.70%-10.42%-24.34%3.10%0.20%-0.23%
Other Income 0.000.000.000.000.000.080.000.000.000.090.090.090.09
Interest 0.000.000.000.000.000.000.000.000.000.000.000.000.00
Depreciation 0.030.040.020.030.030.030.030.030.030.030.030.030.03
Profit before tax -0.04-0.17-0.18-0.42-0.61-0.34-0.53-0.35-0.43-0.490.240.070.05
Tax % 0.00%258.82%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Net Profit -0.04-0.61-0.17-0.42-0.61-0.34-0.53-0.34-0.43-0.490.240.070.05
EPS in Rs -0.13-2.03-0.57-1.40-2.03-1.13-1.77-1.13-1.43-1.630.800.230.17

Last Updated: March 3, 2026, 11:38 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 27, 2026, 2:00 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 34.4238.6546.8859.7855.7165.1849.6234.988.5322.2316.4913.4617.26
Expenses 33.9738.0945.4458.5353.7564.0148.8935.5810.5322.5317.9515.2317.63
Operating Profit 0.450.561.441.251.961.170.73-0.60-2.00-0.30-1.46-1.77-0.37
OPM % 1.31%1.45%3.07%2.09%3.52%1.80%1.47%-1.72%-23.45%-1.35%-8.85%-13.15%-2.14%
Other Income -0.070.040.010.610.090.740.170.310.000.010.080.090.36
Interest 0.140.100.110.070.060.070.050.040.060.010.060.000.00
Depreciation 0.010.030.030.030.030.030.030.030.050.110.100.110.12
Profit before tax 0.230.471.311.761.961.810.82-0.36-2.11-0.41-1.54-1.79-0.13
Tax % 39.13%40.43%27.48%20.45%34.69%26.52%28.05%55.56%-22.27%109.76%-19.48%-3.35%
Net Profit 0.140.280.951.391.281.330.59-0.55-1.64-0.87-1.25-1.74-0.13
EPS in Rs 0.470.933.174.634.274.431.97-1.83-5.47-2.90-4.17-5.80-0.43
Dividend Payout % 0.00%0.00%31.58%32.37%23.44%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)100.00%239.29%46.32%-7.91%3.91%-55.64%-193.22%-198.18%46.95%-43.68%-39.20%
Change in YoY Net Profit Growth (%)0.00%139.29%-192.97%-54.23%11.82%-59.55%-137.58%-4.96%245.13%-90.63%4.48%

Brawn Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:-10%
5 Years:-23%
3 Years:16%
TTM:15%
Compounded Profit Growth
10 Years:%
5 Years:%
3 Years:-3%
TTM:46%
Stock Price CAGR
10 Years:-4%
5 Years:-3%
3 Years:5%
1 Year:15%
Return on Equity
10 Years:-1%
5 Years:-18%
3 Years:-23%
Last Year:-43%

Last Updated: September 5, 2025, 2:46 pm

Balance Sheet

Last Updated: December 4, 2025, 2:34 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 3.003.003.003.003.003.003.003.003.003.003.003.003.00
Reserves 1.681.942.533.924.635.666.265.794.223.312.060.360.70
Borrowings 0.010.110.120.000.000.000.000.000.000.000.000.000.00
Other Liabilities 9.008.958.3010.1114.9413.8511.035.086.568.229.5317.1318.46
Total Liabilities 13.6914.0013.9517.0322.5722.5120.2913.8713.7814.5314.5920.4922.16
Fixed Assets 0.070.190.240.250.220.190.180.140.390.370.330.460.42
CWIP 0.000.000.000.000.000.000.000.000.000.000.000.000.00
Investments 0.030.030.030.000.000.000.000.000.000.000.000.000.00
Other Assets 13.5913.7813.6816.7822.3522.3220.1113.7313.3914.1614.2620.0321.74
Total Assets 13.6914.0013.9517.0322.5722.5120.2913.8713.7814.5314.5920.4922.16

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 0.180.230.051.37-1.540.21-0.080.030.190.32-0.030.05
Cash from Investing Activity + -0.01-0.12-0.080.570.000.00-0.020.00-0.30-0.10-0.01-0.24
Cash from Financing Activity + -0.150.00-0.05-0.11-0.06-0.06-0.05-0.04-0.06-0.010.000.00
Net Cash Flow 0.020.11-0.081.83-1.600.15-0.140.00-0.170.21-0.04-0.20
Free Cash Flow 0.170.11-0.031.34-1.540.21-0.100.03-0.110.22-0.030.05
CFO/OP 40%41%28%170%-14%88%21%-52%-10%-103%2%-3%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow0.440.451.321.251.961.170.73-0.60-2.00-0.30-1.46-1.77

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 88.6587.0771.6379.5098.6092.17110.3496.83120.2487.3585.8892.47
Inventory Days 22.1411.174.502.592.622.123.383.16261.8291.20153.02320.33
Days Payable 87.7973.7244.5947.7083.9364.5874.4732.34224.66123.19144.12252.10
Cash Conversion Cycle 23.0124.5231.5434.3917.2929.7239.2567.65157.4155.3694.78160.70
Working Capital Days 15.4815.8718.9228.2143.3742.0658.0477.53241.7680.62137.90216.40
ROCE %24.89%11.91%26.54%29.28%27.77%23.08%9.71%-3.55%-25.61%-5.91%-25.86%-42.52%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 53.72%53.72%53.72%53.72%53.64%53.64%53.64%53.64%53.66%53.66%53.66%53.39%
DIIs 0.59%0.59%0.59%0.59%0.35%0.35%0.35%0.35%0.35%0.35%0.35%0.35%
Public 45.69%45.69%45.69%45.69%46.02%46.02%46.02%46.02%46.01%46.00%45.99%46.27%
No. of Shareholders 6,2226,2466,1946,1394,1604,0904,1574,0604,0243,9753,9583,444

Shareholding Pattern Chart

No. of Shareholders

Brawn Biotech Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) -5.68-4.15-3.04-5.25-1.55
Diluted EPS (Rs.) -5.68-4.15-3.04-5.25-1.55
Cash EPS (Rs.) -5.42-3.83-2.53-5.30-1.72
Book Value[Excl.RevalReserv]/Share (Rs.) 11.2116.8821.0324.0729.31
Book Value[Incl.RevalReserv]/Share (Rs.) 11.2116.8821.0324.0729.31
Revenue From Operations / Share (Rs.) 44.8854.9874.0928.73116.57
PBDIT / Share (Rs.) -5.60-4.80-0.98-6.67-0.96
PBIT / Share (Rs.) -5.98-5.13-1.34-6.85-1.08
PBT / Share (Rs.) -5.99-5.15-1.37-7.06-1.20
Net Profit / Share (Rs.) -5.80-4.16-2.89-5.48-1.84
PBDIT Margin (%) -12.47-8.73-1.32-23.22-0.82
PBIT Margin (%) -13.32-9.33-1.81-23.84-0.92
PBT Margin (%) -13.35-9.36-1.85-24.56-1.02
Net Profit Margin (%) -12.92-7.56-3.90-19.07-1.57
Return on Networth / Equity (%) -51.75-24.61-13.75-22.77-6.26
Return on Capital Employeed (%) -16.07-19.06-6.21-27.53-3.60
Return On Assets (%) -8.49-8.54-5.97-11.92-3.96
Asset Turnover Ratio (%) 0.761.131.570.622.05
Current Ratio (X) 1.882.021.671.932.60
Quick Ratio (X) 0.751.091.071.182.54
Inventory Turnover Ratio (X) 1.630.000.000.005.09
Interest Coverage Ratio (X) -459.48-380.33-35.76-32.06-7.83
Interest Coverage Ratio (Post Tax) (X) -474.95-328.11-104.52-25.33-13.91
Enterprise Value (Cr.) 4.685.604.534.986.23
EV / Net Operating Revenue (X) 0.340.330.200.570.17
EV / EBITDA (X) -2.78-3.89-15.39-2.49-21.54
MarketCap / Net Operating Revenue (X) 0.360.360.220.600.18
Price / BV (X) 1.451.180.780.720.75
Price / Net Operating Revenue (X) 0.360.360.220.600.18
EarningsYield -0.35-0.20-0.17-0.31-0.08

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Brawn Biotech Ltd. is a Public Limited Listed company incorporated on 07/11/1985 and has its registered office in the State of Delhi, India. Company's Corporate Identification Number(CIN) is L74899DL1985PLC022468 and registration number is 022468. Currently Company is involved in the business activities of Wholesale of pharmaceutical and medical goods. Company's Total Operating Revenue is Rs. 13.46 Cr. and Equity Capital is Rs. 3.00 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsC-64, First Floor, New Delhi Delhi 110024Contact not found
Management
NamePosition Held
Mr. Brij Raj GuptaDirector
Mrs. Brij Bala GuptaDirector
Mr. Mayank JainIndependent Director
Mrs. Pooja JhaIndependent Director

FAQ

What is the intrinsic value of Brawn Biotech Ltd and is it undervalued?

As of 14 April 2026, Brawn Biotech Ltd's intrinsic value is ₹51.96, which is 149.81% higher than the current market price of ₹20.80, suggesting the stock is undervalued. This is calculated using the PE ratio method factoring in ROE (41.3 %), book value (₹12.3), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Brawn Biotech Ltd?

Brawn Biotech Ltd is trading at ₹20.80 as of 14 April 2026, with a FY2026-2027 high of ₹24.4 and low of ₹15.7. The stock is currently in the middle of its 52-week range. Market cap stands at ₹6.26 Cr..

How does Brawn Biotech Ltd's P/E ratio compare to its industry?

Brawn Biotech Ltd has a P/E ratio of , which is below the industry average of 53.84. This is broadly in line with or below the industry average.

Is Brawn Biotech Ltd financially healthy?

Key indicators for Brawn Biotech Ltd: ROCE of 42.5 % indicates efficient capital utilization; ROE of 41.3 % shows strong shareholder returns. Dividend yield is 0.00 %.

Is Brawn Biotech Ltd profitable and how is the profit trend?

Brawn Biotech Ltd reported a net profit of ₹-2 Cr in Mar 2025 on revenue of ₹13 Cr. Compared to ₹-2 Cr in Mar 2022, the net profit shows a mixed trend.

Does Brawn Biotech Ltd pay dividends?

Brawn Biotech Ltd has a dividend yield of 0.00 % at the current price of ₹20.80. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Brawn Biotech Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports